France expects fewer doses of AstraZeneca vaccine in February, before recovering in March, and the arrival of Janssen’s vaccine is expected in May instead of April, the health ministry said Tuesday.
«We will reach 1.7 million doses of AstraZeneca in February instead of 2.5, which we originally planned»,«but it’s a shift “and” when we combine February and March, we fall back on our feet with 5.9 million cumulative doses“, We told the ministry during a weekly update on faxes.
According to the same source, after a delivery of 550,000 doses last week, the same number is expected this week and around 850,000 doses are expected to arrive next week. The expected total of almost 6 million doses at the end of March is already below previous forecasts, which were set at 9 million at the end of the first quarter. At the Ministry of Health, we place special emphasis on the problem of using these doses, and give that “we have a question of image shortage for AstraZenecaThat should be addressed after questions have been asked about the side effects and effectiveness.
For now, this vaccine is reserved for people aged 50 to 64 with co-morbidities, or about two million people, and health care under 65. The Haute Autorité de Santé (HAS) does not currently recommend it for older age groups due to a deficiency to data. However, on a visit to the Economic, Social and Environmental Council (CESE), Health Minister Olivier Véran claimed on Tuesday that a Scottish study released on Monday, not yet evaluated by other scientists, showedabsolutely phenomenal effectiveness of AstraZeneca in the elderly, even 65 years and older».
«We should no longer be in a problem of stress on the doses»
Regarding the fax of Janssen, a subsidiary of the American Johnson & Johnson, “arrival must take place in May“, Added the ministry, while earlier forecasts, at the beginning of February, counted on 2.7 million doses in April. “The lab tells us that April seems difficult to her” most “the hypothesis is still validated, it is the ‘worst case scenario’», Adds the same source.
However, “we should no longer be in a problem of stresses on the doses»At present, with more than 30 million cumulative doses planned in France in April for the first three vaccines authorized in Europe (Pfizer / BioNTech, Moderna, AstraZeneca), the Ministry of Health emphasizes.